Literature DB >> 22122641

New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators.

Sophie Rousseaux1, Saadi Khochbin.   

Abstract

Oncogenic cell transformation is consistently associated with alterations of the cell epigenome leading to aberrant gene repression and activation. Some of these events, such as the DNA-methylation-based silencing of tumor suppressor genes, are considered to be oncogenic themselves. A much less-studied consequence of these epigenetic misregulations is the abnormal activation of tissue-specific genes in precancerous and transformed cells. Here, we explore the idea that the aberrant expression of germ-cell-specific genes in somatic cancer cells could contribute to malignant cell transformation and cancer progression. Indeed, a significant number of papers have reported the abnormal activation of germ cell-specific genes in various somatic cancers (known as cancer testis [C/T] antigens or factors). Although in most cases the physiological function of these genes remains unknown, functional investigations suggest that they can act as potent genome, epigenome and cellular reorganizers. Hence, in view of the existing literature, we discuss the hypothesis that C/T activation in somatic cells is not only a consequence of global epigenetic deregulation, but also a cause of further large-scale alterations of the epigenome, which themselves have direct oncogenic consequences for the affected cells. Finally, we highlight the fact that C/T factors have the potential to serve as valuable markers for cancer detection, as well as provide promising targets for developing new therapeutical strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 22122641     DOI: 10.2217/epi.09.1

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  11 in total

1.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.

Authors:  Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

2.  BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Authors:  Anna Woloszynska-Read; Smitha R James; Chajoun Song; Boquan Jin; Kunle Odunsi; Adam R Karpf
Journal:  Cancer Immun       Date:  2010-07-23

3.  Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers.

Authors:  Sophie Rousseaux; Alexandra Debernardi; Baptiste Jacquiau; Anne-Laure Vitte; Aurélien Vesin; Hélène Nagy-Mignotte; Denis Moro-Sibilot; Pierre-Yves Brichon; Sylvie Lantuejoul; Pierre Hainaut; Julien Laffaire; Aurélien de Reyniès; David G Beer; Jean-François Timsit; Christian Brambilla; Elisabeth Brambilla; Saadi Khochbin
Journal:  Sci Transl Med       Date:  2013-05-22       Impact factor: 17.956

4.  Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.

Authors:  Anna Woloszynska-Read; Wa Zhang; Jihnhee Yu; Petra A Link; Paulette Mhawech-Fauceglia; Golda Collamat; Stacey N Akers; Kelly R Ostler; Lucy A Godley; Kunle Odunsi; Adam R Karpf
Journal:  Clin Cancer Res       Date:  2011-02-04       Impact factor: 12.531

Review 5.  Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.

Authors:  Stacey N Akers; Kunle Odunsi; Adam R Karpf
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.404

6.  ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.

Authors:  Hye Won Hwang; Sang Yun Ha; Heejin Bang; Cheol-Keun Park
Journal:  Cancer Res Treat       Date:  2015-02-16       Impact factor: 4.679

7.  Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.

Authors:  Anouk Emadali; Sophie Rousseaux; Juliana Bruder-Costa; Claire Rome; Samuel Duley; Sieme Hamaidia; Patricia Betton; Alexandra Debernardi; Dominique Leroux; Benoit Bernay; Sylvie Kieffer-Jaquinod; Florence Combes; Elena Ferri; Charles E McKenna; Carlo Petosa; Christophe Bruley; Jérôme Garin; Myriam Ferro; Rémy Gressin; Mary B Callanan; Saadi Khochbin
Journal:  EMBO Mol Med       Date:  2013-07-04       Impact factor: 12.137

Review 8.  The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target.

Authors:  Ekaterina Bourova-Flin; Florent Chuffart; Sophie Rousseaux; Saadi Khochbin
Journal:  Cell J       Date:  2017-05-17       Impact factor: 2.479

Review 9.  Short Histone H2A Variants: Small in Stature but not in Function.

Authors:  Xuanzhao Jiang; Tatiana A Soboleva; David J Tremethick
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

10.  H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma.

Authors:  Xuanzhao Jiang; Jiayu Wen; Elizabeth Paver; Yu-Huan Wu; Gege Sun; Amanda Bullman; Jane E Dahlstrom; David J Tremethick; Tatiana A Soboleva
Journal:  EMBO Rep       Date:  2021-07-19       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.